PMID- 35712973
OWN - NLM
STAT- MEDLINE
DCOM- 20220830
LR  - 20221205
IS  - 2005-0399 (Electronic)
IS  - 2005-0380 (Print)
IS  - 2005-0380 (Linking)
VI  - 33
IP  - 5
DP  - 2022 Sep
TI  - Efficacy of edoxaban for the treatment of gynecological cancer-associated venous 
      thromboembolism: analysis of Japanese real-world data.
PG  - e62
LID - 10.3802/jgo.2022.33.e62 [doi]
LID - e62
AB  - OBJECTIVE: Direct oral anticoagulants (DOACs) are increasingly being used for the 
      treatment of cancer-associated venous thromboembolism (CAT). However, there is 
      limited evidence of the efficacy of DOACs for the treatment of gynecological CAT. 
      Thus, this study aimed to investigate the efficacy and safety of edoxaban for the 
      treatment of gynecological CAT using Japanese real-world data. METHODS: We 
      reviewed the medical records of patients with 371 gynecological cancer who 
      received edoxaban or vitamin K antagonist (VKA) between January 2011 and December 
      2018. RESULTS: Altogether, 211 and 160 patients were treated with edoxaban and 
      VKA, respectively. Fourteen patients (6.8%) in the edoxaban group and 22 (13.8%) 
      in the VKA group showed recurrence of venous thromboembolism (VTE). Cumulative 
      VTE recurrence was not significantly different between the 2 groups (p=0.340). 
      Adverse events occurred in 15 (7.1%) and 11 (6.9%) patients in the edoxaban and 
      VKA groups, respectively (p=0.697). Subgroup analysis of the edoxaban and VKA 
      groups according to different tumor types, including ovarian, endometrial, and 
      cervical cancer, showed equivalent outcomes in terms of VTE recurrence and 
      adverse events. Patients without pulmonary embolism (PE) were mostly omitted from 
      initial unfractionated heparin (UFH) therapy prior to administration of edoxaban. 
      However, this did not increase the recurrence of VTE. CONCLUSION: This study 
      confirmed that edoxaban is effective and safe for the treatment of gynecological 
      CAT. This finding was consistent for different types of gynecological cancer. 
      Additionally, initial UFH therapy prior to the administration of edoxaban may be 
      unnecessary for patients without PE.
CI  - (c) 2022. Asian Society of Gynecologic Oncology, Korean Society of Gynecologic 
      Oncology, and Japan Society of Gynecologic Oncology.
FAU - Odajima, Suguru
AU  - Odajima S
AUID- ORCID: 0000-0003-1000-1974
AD  - Department of Obstetrics and Gynecology, The Jikei University School of Medicine, 
      Tokyo, Japan.
FAU - Seki, Toshiyuki
AU  - Seki T
AUID- ORCID: 0000-0002-7559-7089
AD  - Department of Obstetrics and Gynecology, The Jikei University School of Medicine, 
      Tokyo, Japan. t_seki@jikei.ac.jp.
FAU - Kato, Sayako
AU  - Kato S
AUID- ORCID: 0000-0001-5188-5783
AD  - Department of Obstetrics and Gynecology, Daisan Hospital, The Jikei University 
      School of Medicine, Tokyo, Japan.
FAU - Tomita, Keisuke
AU  - Tomita K
AUID- ORCID: 0000-0002-1661-8097
AD  - Department of Obstetrics and Gynecology, Kashiwa Hospital, The Jikei University 
      School of Medicine, Chiba, Japan.
FAU - Shoburu, Yuichi
AU  - Shoburu Y
AUID- ORCID: 0000-0001-6533-3234
AD  - Department of Obstetrics and Gynecology, The Jikei University School of Medicine, 
      Tokyo, Japan.
FAU - Suzuki, Eitaro
AU  - Suzuki E
AUID- ORCID: 0000-0002-9684-8860
AD  - Department of Obstetrics and Gynecology, Katsushika Medical Center, The Jikei 
      University School of Medicine, Tokyo, Japan.
FAU - Takenaka, Masataka
AU  - Takenaka M
AUID- ORCID: 0000-0002-3833-4730
AD  - Department of Obstetrics and Gynecology, The Jikei University School of Medicine, 
      Tokyo, Japan.
FAU - Saito, Motoaki
AU  - Saito M
AUID- ORCID: 0000-0001-6764-8459
AD  - Department of Obstetrics and Gynecology, Kashiwa Hospital, The Jikei University 
      School of Medicine, Chiba, Japan.
FAU - Takano, Hirokuni
AU  - Takano H
AUID- ORCID: 0000-0002-6465-7883
AD  - Department of Obstetrics and Gynecology, Katsushika Medical Center, The Jikei 
      University School of Medicine, Tokyo, Japan.
FAU - Yamada, Kyosuke
AU  - Yamada K
AUID- ORCID: 0000-0002-5216-7297
AD  - Department of Obstetrics and Gynecology, Daisan Hospital, The Jikei University 
      School of Medicine, Tokyo, Japan.
FAU - Okamoto, Aikou
AU  - Okamoto A
AUID- ORCID: 0000-0002-5079-0464
AD  - Department of Obstetrics and Gynecology, The Jikei University School of Medicine, 
      Tokyo, Japan.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20220607
PL  - Korea (South)
TA  - J Gynecol Oncol
JT  - Journal of gynecologic oncology
JID - 101483150
RN  - 0 (Anticoagulants)
RN  - 0 (Pyridines)
RN  - 0 (Thiazoles)
RN  - 9005-49-6 (Heparin)
RN  - NDU3J18APO (edoxaban)
SB  - IM
MH  - Administration, Oral
MH  - Anticoagulants
MH  - Heparin
MH  - Humans
MH  - Japan
MH  - *Neoplasms
MH  - *Pulmonary Embolism
MH  - Pyridines
MH  - Thiazoles
MH  - *Venous Thromboembolism
PMC - PMC9428303
OTO - NOTNLM
OT  - Anticoagulant Drugs
OT  - Gynecologic Neoplasm
OT  - Venous Thromboembolism
COIS- No potential conflict of interest relevant to this article was reported.
EDAT- 2022/06/18 06:00
MHDA- 2022/08/31 06:00
PMCR- 2022/09/01
CRDT- 2022/06/17 04:23
PHST- 2022/01/11 00:00 [received]
PHST- 2022/05/11 00:00 [revised]
PHST- 2022/05/23 00:00 [accepted]
PHST- 2022/06/18 06:00 [pubmed]
PHST- 2022/08/31 06:00 [medline]
PHST- 2022/06/17 04:23 [entrez]
PHST- 2022/09/01 00:00 [pmc-release]
AID - 33.e62 [pii]
AID - 10.3802/jgo.2022.33.e62 [doi]
PST - ppublish
SO  - J Gynecol Oncol. 2022 Sep;33(5):e62. doi: 10.3802/jgo.2022.33.e62. Epub 2022 Jun 
      7.